Viva Biotech (01873) sells shares in an investment incubation company

Zhitong Financial App News, Viva Biotech (01873) announced that Arthrosi Therapeutics will meet the company. On December 13, 2025, the buyer Sobi US Holding Corp. has agreed to acquire Arthrosi Therapeutics through a merger and acquisition. Following completion, the Company will no longer hold any shares in Arthrosi Therapeutics. The merger and acquisition agreement stipulates an advance payment of $950 million (subject to customary adjustments) and possibly no more than $550 million to be paid upon completion.

Arthrosi Therapeutics is a Delaware company, a clinical-stage biotechnology company focusing on the development of pozdeutinurad, a potentially best-in-class, high-efficacy, and next-generation URAT1 inhibitor designed to reduce serum uric acid levels and reduce acute attacks and gout stones in patients with progressive gout. As of the date of this announcement, Viva Incubator held approximately 3.14% of Arthrosi Therapeutics' share capital (calculated on a fully diluted and converted basis).

The directors believe that the merger and acquisition will enable the Group to realize the value of its investment in Arthrosi Therapeutics accumulated over a long period of time since the investment, and is currently an opportunity to enhance the Group's financial flexibility. The Group intends to use the proceeds from mergers and acquisitions to supplement the Group's working capital and support the growth and development of the Group's other investments and incubation businesses.